.jpg?bc=ffffff&h=525&w=1000&rev=02926ce6f4d6426c9342b1675cfb58c1&hash=B7E2D6FB448A5F9A72A8F3110192B112)
The MOU was signed by Prof CHOW Ming-cheung, Larry (3rd from right) and Mr. Shixin FAN, Board Director of ChemPartner (3rd from left). Other guests joining the ceremony included Mr. William WOO, Chairman and CEO of ChemPartner (2nd from left), Mr. Yinqun ZHA, CFO of ChemPartner (1st from left), Prof ZHAO Yanxiang, Associate Head and Professor of Department of Applied Biology and Chemical Technology of PolyU (2nd from right) and Prof Thomas Leung, Professor at Department of Applied Biology and Chemical Technology of PolyU (1st from right).
The Hong Kong Polytechnic University (PolyU) and Shanghai ChemPartner Co. Ltd. (ChemPartner) signed a Memorandum of Understanding (MOU) on 9 August to establish the partnership and jointly develop next-generation cancer immunotherapy agents.
This partnership combines expertise from both academia and industry, with the long-term goal of benefiting cancer patients. PolyU continues to advance its novel targets into personalised cancer treatments based on antibodies. The collaboration integrates the University's strengths in fundamental scientific research and the industry's translational expertise, creating a synergistic relationship.
The partnership aims to bridge research on drug development, accelerating innovation and commercialisation of cancer treatments. This synergy promotes knowledge exchange and resources, paving the way for oncology advancements.
The MOU was signed by Prof. CHOW Ming-cheung, Larry, Head and Professor of the Department of Applied Biology and Chemical Technology of PolyU, and Mr Shixin FAN, Board Director of ChemPartner.
Prof. CHOW said, "This partnership exemplifies the need for academia and industry to collaborate closely to achieve success. To achieve complementary advantages, we will focus on the early discovery phase of markers, while ChemPartner will work on the later stages of antibody development."
Mr. William Woo, Chairman and CEO of ChemPartner, said, "We hope that through this partnership, we can promote exchanges and collaboration between the two sides in the field of medical technology, share resources, complement each other's strengths, and jointly make greater contributions to human health."
